Q3 Earnings Estimate for Exelixis Issued By Zacks Research

Exelixis, Inc. (NASDAQ:EXEL) – Research analysts at Zacks Research raised their Q3 2026 earnings per share estimates for Exelixis in a report released on Friday, March 6th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings of $0.74 per share for the quarter, up from their prior forecast of $0.71. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ FY2026 earnings at $2.96 EPS, Q1 2027 earnings at $0.82 EPS and FY2028 earnings at $4.23 EPS.

Other research analysts have also issued research reports about the stock. Bank of America lowered shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price for the company. in a research note on Monday, January 5th. Barclays boosted their price target on shares of Exelixis from $41.00 to $44.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 4th. Stifel Nicolaus upped their price objective on shares of Exelixis from $43.00 to $44.00 and gave the stock a “hold” rating in a report on Wednesday, February 11th. Wall Street Zen cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 2nd. Finally, Morgan Stanley lifted their target price on shares of Exelixis from $48.00 to $49.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Ten investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $46.94.

Exelixis Trading Up 0.6%

Shares of EXEL opened at $41.54 on Monday. The firm has a market cap of $10.79 billion, a P/E ratio of 15.00, a price-to-earnings-growth ratio of 0.93 and a beta of 0.41. Exelixis has a 12-month low of $32.38 and a 12-month high of $49.62. The company’s 50-day moving average price is $43.57 and its 200 day moving average price is $41.60.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. The business had revenue of $598.66 million during the quarter, compared to analysts’ expectations of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The company’s revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.55 EPS.

Hedge Funds Weigh In On Exelixis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Motiv8 Investments LLC purchased a new stake in shares of Exelixis during the fourth quarter worth $26,000. Richardson Financial Services Inc. raised its stake in shares of Exelixis by 95.1% in the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 292 shares in the last quarter. Anchor Investment Management LLC boosted its holdings in Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares during the period. Acumen Wealth Advisors LLC purchased a new position in Exelixis in the fourth quarter valued at $29,000. Finally, Root Financial Partners LLC acquired a new position in Exelixis during the 3rd quarter worth $28,000. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Activity at Exelixis

In other news, Director Jack L. Wyszomierski sold 99,574 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total transaction of $4,382,251.74. Following the sale, the director owned 279,942 shares of the company’s stock, valued at approximately $12,320,247.42. This represents a 26.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Brenda Hefti sold 18,669 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total transaction of $821,622.69. Following the completion of the transaction, the senior vice president directly owned 96,512 shares of the company’s stock, valued at approximately $4,247,493.12. The trade was a 16.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 362,849 shares of company stock valued at $15,917,463. 2.82% of the stock is owned by company insiders.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.